Capecitabine

Chemical formula: C₁₅H₂₂FN₃O₆  Molecular mass: 359.35 g/mol  PubChem compound: 60953

Therapeutic indications

Capecitabine is indicated for:

Gastric cancer

Population group: only adults (18 years old or older)

Capecitabine is indicated for the treatment of first-line treatment of advanced gastric cancer in combination with a platinum based regimen.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Breast cancer

Population group: only adults (18 years old or older)

Capecitabine is indicated for the treatment of:

  • in combination with docetaxel for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.
  • as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Colorectal cancer

Population group: only adults (18 years old or older)

Capecitabine is indicated for the treatment of:

  • for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer.
  • metastatic colorectal cancer.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Capecitabine is contraindicated in the following cases:

Severe leucopenia, neutropenia, thrombocytopenia

at least one of
Leukopenia
Neutropenia
Thrombocytopenic disorder

Pregnancy

Pregnancy

Lactation

Lactation

Dihydropyrimidine dehydrogenase (DPD) deficiency

Dihydrouracil dehydrogenase (NADP^+^) deficiency

Severe hepatic impairment

Hepatic failure stage IV

Severe renal impairment (creatinine clearance below 30 ml/min)

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Brivudine, sorivudine

at least one of
Brivudine
SORIVUDINE

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: CAPECITABINE ACCORD Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈